A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Ceritinib (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 26 Mar 2019 Planned number of patients changed from 96 to 38.
- 26 Mar 2019 Planned primary completion date changed from 11 Mar 2019 to 11 Apr 2019.
- 26 Mar 2019 Status changed from recruiting to active, no longer recruiting.